Compare KTB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTB | IOVA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 968.6M |
| IPO Year | N/A | N/A |
| Metric | KTB | IOVA |
|---|---|---|
| Price | $66.55 | $2.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $96.38 | $10.36 |
| AVG Volume (30 Days) | 643.7K | ★ 9.8M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $2,833,659,000.00 | $250,425,000.00 |
| Revenue This Year | $20.46 | $60.94 |
| Revenue Next Year | $11.11 | $60.85 |
| P/E Ratio | $17.15 | ★ N/A |
| Revenue Growth | 9.91 | ★ 175.62 |
| 52 Week Low | $50.00 | $1.64 |
| 52 Week High | $96.80 | $8.56 |
| Indicator | KTB | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 34.26 | 44.43 |
| Support Level | $65.89 | $2.18 |
| Resistance Level | $69.73 | $2.32 |
| Average True Range (ATR) | 2.77 | 0.11 |
| MACD | -0.66 | -0.02 |
| Stochastic Oscillator | 0.00 | 7.36 |
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.